Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome

• Published in: Clinical immunology (Orlando, Fla.) Vol. 183; pp. 300 - 303
• Main Authors: Nezos, Adrianos, Cinoku, Ilir, Mavragani, Clio P., Moutsopoulos, Haralampos M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2017
• Subjects: Aged; Antibodies against citrullinated peptides (ACPA); Antibody Specificity; Autoantibodies; Citrullinated alpha enolase (CEP-1); Female; Humans; Male; Middle Aged; Phosphopyruvate Hydratase - immunology; Primary Sjogren's syndrome; Sjogren's Syndrome - immunology; Vimentin - immunology; Vimentin - metabolism; Primary Sjogren's syndrome; Autoantibodies; Antibodies against citrullinated peptides (ACPA); Citrullinated alpha enolase (CEP-1)
• ISSN: 1521-6616; 1521-7035
• DOI: 10.1016/j.clim.2017.09.012

Citrullinated alpha enolase (CEP-1) has been designated as a major antigenic target of antibodies against citrullinated proteins (ACPA) in patients with rheumatoid arthritis (RA). Our aim is to determine the prevalence of anti-CEP-1 in a cohort of ACPA positive (ACPA+) primary Sjogren's syndrome (pSS) patients. Anti-CEP1 titers were determined by ELISA in sera from 15 ACPA+ and 45 ACPA- age/sex matched pSS; 12 ACPA+ RA patients and 30 healthy controls (HC). Increased anti-CEP-1 antibody titers were detected in nine out of the 15 (60%) ACPA+ pSS patients and 5 out of 12 (41.7%) ACPA+ RA patients; no reactivities were detected in ACPA- pSS patients and HC. Anti-CEP-1 antibodies in the setting of pSS were associated with higher urine pH levels at baseline. CEP-1 is a major antigenic target of ACPA in patients with pSS characterizing a subgroup with distinct laboratory features. •CEP-1 is a major antigenic target of ACPA in patients with pSS.•Anti-CEP-1 antibodies are associated with increased rates of non-erosive arthritis.•Anti-CEP-1 antibodies are associated with higher urine pH at baseline.